Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Relay Therapeutics, Inc.

Now might be a great time for investors to consider investing in precision medicine stocks. For those who don't know, precision medicine is an approach to disease treatment and prevention that tailors medical decisions to the individual patient.

3 Precision Medicine Stocks That Could Benefit From the Industry's Rise

Moderna stock rallied 9% yesterday, after it launched phase 2/phase 3 clinical trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck. As per an earlier study, a combination of the vaccine and Merck's blockbuster Keytruda immunotherapy resulted in a significant improvement in recurrence-free survival time in patients with late-stage melanoma.

What's Next For Moderna Stock After Nearly A 20% Rise In A Week?

Many investors still see Moderna as a coronavirus stock and have questioned growth prospects. The main bull case for Moderna is that it's poised to return to growth soon.

Moderna Stock: Bull vs. Bear

Moderna, Inc. (MRNA) Barclays 26th Annual Global Healthcare Conference (Transcript)

Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.

Why Moderna (MRNA) Stock Price Was Up 9% on Monday

Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?

Moderna stock surged Monday, nearing its first breakout in over a year, after launching a third study of its cancer vaccine.

Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test

As the pandemic recedes, Moderna is laying off some manufacturing staff. But it isn't slowing down the work on its most promising pipeline programs.

1 (Bad) Reason to Sell Moderna Stock Right Now, and 2 Good Reasons to Buy It

Target

Zoom Video

As an investor, you never really know how your investments will play out. Some companies that have been in long-term decline can suddenly become turnaround stocks and rise again, surprising everyone.

Turnaround Plays: 3 Stocks to Buy for a Major Recovery in 2024

Illumina

Incyte

The global oncology ecosystem is at a pivotal juncture. Significant advancements in discovery, development, and delivery of novel cancer treatments are enhancing patient outcomes.

3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise

Moderna, Inc. (NASDAQ:MRNA ) TD Cowen 44th Annual Health Care Conference March 6, 2024 1:30 PM ET Company Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good afternoon, everyone. Thanks for being here.

Moderna, Inc. (MRNA) TD Cowen 44th Annual Health Care Conference (Transcript)

Ironwood Pharma

Novavax

Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, treatment authorization, or any number of events that could be or break a company.

It's Time! 3 Failing Biotech Stocks to Sell Right Now

CRISPR Therapeutics

Vertex Pharmaceuticals

ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day.

ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential

Moderna's sales plunged in 2023 as demand for its COVID vaccine has been diminishing. The company has multiple products in its pipeline that could be key parts of its business in five years.

Where Will Moderna Stock Be in 5 Years?

Apple

Ford Motor Company

Lululemon Athletica

Roku

Lululemon is showing no signs of slowing down. Moderna and Roku are poised for a comeback.

5 Top Stocks to Buy in March

Eli Lilly

Eli Lilly could have the world's future best-selling drug in its lineup. Moderna is poised to expand beyond COVID with several new products potentially on the way.

3 Magnificent Growth Stocks to Buy in March

Moderna stock soared on a strong fourth-quarter report that included unexpected earnings. Is MRNA stock a buy or a sell right now?

Is Moderna Stock A Buy After Surprise Profit Sends Shares Flying?

CAMBRIDGE, MA / ACCESSWIRE / February 29, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its fifth annual Investor Event focused on vaccines and business updates on Wednesday, March 27, 2024. The presentation will begin at 9:00 a.m.

Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024

Intellia Therapeutics

Intellia has big goals for the coming couple of years, including filing for regulatory review of what could become its first commercialized product. Moderna could have better days ahead with a big potential regulatory approval within the next few months.

A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now

Carvana

NVIDIA

Block

Earnings season for the fourth quarter of calendar 2023 is coming to a close. Clear winners and losers are emerging from the reports.

Earnings Seasons Score Card: 4 Stock Superstars and 3 That Fell Short

CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conference, on Wednesday March 6th at 1:30 pm ET. Barclays 26th Annual Global Healthcare Conference, on Tuesday March 12th at 2:35 pm ET.

Moderna to Present at Upcoming Investor Conferences in March 2024

Moderna is trying to move on from its coronavirus vaccine heyday. Its respiratory syncytial virus (RSV) vaccine could launch this year.

Moderna Stock Has 33% Upside, According to 1 Wall Street Analyst

Elis closes the acquisition of Moderna Holding BV in the Netherlands Saint-Cloud, 26 February 2024 – Elis, the global leader in circular services at work, today announces the acquisition of 100% of Moderna Holding BV (« Moderna ») in the Netherlands, which signing was announced on 10 January 2024. The acquisition will be consolidated from 1 March 2024.

Elis closes the acquisition of Moderna Holding BV in the Netherlands

Energy Transfer LP Unit

Simon Property Group

Despite a strong run, this energy MLP is still offering investors an outstanding entry point and a hefty 8.52% dividend.

3 Dividend Stocks I Wish I Bought Last Year And 1 I Like Now

Moderna (NASDAQ: MRNA) stock significantly surged on February 22 after the company surpassed Wall Street's quarterly expectations.

News for Moderna Stock (MRNA)